12:00 AM
 | 
Apr 06, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ophena ospemifene: Phase III

QuatRx completed enrollment of over 900 postmenopausal women in a double-blind, placebo-controlled, U.S. Phase III trial evaluating 60 mg of oral Ophena given once daily for...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >